Phio Pharmaceuticals Announces Upcoming Presentation at the SITC 36th Annual Meeting.
ENPNewswire-October 19, 2021--Phio Pharmaceuticals Announces Upcoming Presentation at the SITC 36th Annual Meeting
(C)2021 ENPublishing - http://www.enpublishing.co.uk
Release date- 18102021 - MARLBOROUGH, Mass. - Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, announced that new data suggesting a systemic immune response can be generated with its lead clinical product candidate, PH-762, after local administration. These data will be presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, being held in Washington, D.C. on November 10-14, 2021.
Presentation Details are as follows:
Title: Locally administered immunotherapy self-delivering RNAi PH-762 results in abscopal clearance of untreated distal tumors, suggesting systemic immune response, in a murine hepatocarcinoma model
Abstract Number: 869
Author: Benjamin Cuiffo, et al.
Time and Date: 7:00 am - 8:30 pm ET on 11/12/2021
Location: Poster Hall - Hall E
Poster presentations will be accessible in person and virtually. Posters will released on the SITC website at 7:00 am ET on November 12, 2021 and will also be made available on the 'Investors - Events and Presentations' section of the Company's website.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as 'intends,' 'believes,' 'anticipates,' 'indicates,' 'plans,' 'expects,' 'suggests,' 'may,' 'would,' 'should,' 'potential,' 'designed to,' 'will,' 'ongoing,'...
To continue reading
Request your trial